Pear Healthcare Playbook

Lessons from AmirAli Talasaz, Guardant Health, Building a leading precision oncology company to IPO

Jun 30, 2022

43:40

Creator website

Highlights

AI Chapters

Episode notes

How Do You Make Decisions on Product Development?

02:45

Early Adopters and Customer Profiles

02:35

Challenges in Scaling

02:32

Introduction

2min

Garden Health - What Was It Like Growing Up?

5min

The Vision of Garden

2min

The Impact of Garden Health Products on Cancer Patients

6min

What Was the Mission Impossible for a Liquid Biopsy?

3min

Pivoting on the Technology Stack

2min

What's Your Product Market Fit?

3min

Early Adopters and Customer Profiles

3min

What Was the Most Important Factor to Getting Early Adopters?

3min

10.

Challenges in Scaling

3min

11.

How Do You Make Decisions on Product Development?

3min

12.

Scaling and Scaling a Startup

2min

13.

Healthcare Playbook Podcast - Cancer Moonshot 1.0 - What's That Look Like?

4min

14.

Can AI Machine Learning Be Used to Improve Cancer Screening?

4min

This week, we’re super excited to have AmirAli Talasaz, co-CEO and co-founder of Guardant Health, a leading precision oncology company focused on helping conquer cancer globally.

Founded in 2011, Guardant Health is focused on helping conquer cancer through the use of its proprietary blood-based tests, vast data sets and advanced analytics. Guardant’s solutions include treatment selection, recurrence detection and early detection of cancer. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.

Through multiple rounds of private financing, Guardant Health raised over $500 million from investors including Sequoia, Khosla, Lightspeed, OrbiMed, and Softbank, and Pear! and Guardant completed a successful IPO in October 2018.